Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Mta3.4

Methandrostenolone (Dianabol) – Forschung

Überwiegend Mechanismus / Beobachtung

9 begutachtete Studien

Was die Evidenz sagt

Überwiegend Mechanismus / Beobachtung

Die meisten Studien zu Methandrostenolone (Dianabol) sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.

Die meiste Evidenz stammt aus mittelwertigen randomisierten Studien, veröffentlicht 1967–1990 mit einer typischen Studiengröße von 11 Teilnehmenden.

Basierend auf 9 Studien · 5 RCTs · 23 Teilnehmende insgesamt

Konfidenz

Mittlere Konfidenz

Nach Outcome

Lean mass & nitrogen balanceIn doppelblinden Crossover-Studien führten 100 mg/Tag zu einer Zunahme der fettfreien Masse um ~3,3 kg mit vergrößertem Muskelquerschnitt; die Beinkraft stieg bei trainierten Kraftsportlern signifikant gegenüber Placebo · Wochen
Überwiegend Mechanismus / Beobachtung4 Studien
Strength & performanceIn doppelblinden Crossover-Studien führten 100 mg/Tag zu einer Zunahme der fettfreien Masse um ~3,3 kg mit vergrößertem Muskelquerschnitt; die Beinkraft stieg bei trainierten Kraftsportlern signifikant gegenüber Placebo · Wochen
Überwiegend Mechanismus / Beobachtung4 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung3 Studien
Liver & hepatotoxicity
Zu wenige bewertete Studien2 Studien
Hormones & virilization
Zu wenige bewertete Studien2 Studien
Cholesterol & lipids
Zu wenige bewertete Studien1 Studie

Ältere Forschungsbasis

Neueste Studie von 1990

196719781990

1RCT1981

Aloia JF, Kapoor A, Vaswani A, Cohn SH · Metabolism (1981)

Quelle ansehen

2RCT1981

Hervey GR, Knibbs AV, Burkinshaw L, Morgan DB, Jones PR, Chettle DR · Clin Sci (Lond) (1981)

Quelle ansehen

3RCT1967

Hunter PR, Cotton SG, Kelsey JH, Bloom A · Br Med J (1967)

Quelle ansehen

4RCT1976

Selvini A, Martinesi L, Corallo S, Belli C, Lucchelli PE, Binelli C · G Ital Cardiol (1976)

5RCTn=11 · very small study1976

Einfach gesagt: On methandienone the subjects gained weight (mean 3.3 kg) and accumulated a disproportionately large amount of potassium (420 mmol); the increase in weight was confined to the lean part of the body, and the muscles increased in size.

Hervey GR, Hutchinson I, Knibbs AV, Burkinshaw L, Jones PR, Norgan NG, et al. · Lancet (London, England) (1976)

The foundational controlled trial: 11 athletic men given methandienone 100 mg/day for 6 weeks in a double-blind crossover during weight-training
On the drug the men gained a mean ~3.3 kg of body weight that was confined to the lean compartment, with a disproportionately large accumulation of total body potassium and increased muscle size
Strength and performance improved over each training period but not significantly more on drug than placebo — an honest caveat the 1981 follow-up was designed to resolve

Quelle ansehen

6Kohorten=11 · very small study1985

Einfach gesagt: The HDL2 cholesterol concentration decreased by about 80% and HDL3 cholesterol by about 55% ... the study group had significantly lower HDL cholesterol concentrations than the control group.

Alén M, Rahkila P, Marniemi J · International journal of sports medicine (1985)

Counter-evidence on the adverse lipid harm: a controlled clinical trial of power athletes self-administering testosterone and anabolic steroids (including methandrostenolone) versus training controls over 9 months
HDL and HDL2 cholesterol fell dramatically on androgens — HDL2 by ~80% and HDL3 by ~55% — to extremely low concentrations, with the difference from controls significant from 8 to 32 weeks
Quantifies the severe, atherogenic lipid shift that accompanies anabolic-steroid use in real-world dosing, with no offsetting cardiovascular benefit

Quelle ansehen

7Tierstudie1981

Einfach gesagt: The long-term effects of an anabolic steroid (Dianabol) on the liver of motor-active mice was investigated. The pathologic changes occurring are due to cholestasis, peliosis hepatis, and diffuse hepatitis.

Stang-Voss C, Appell HJ · International journal of sports medicine (1981)

Compound-specific hepatotoxicity evidence: a long-term study of Dianabol (methandrostenolone) in motor-active mice examining liver parenchyma
Produced cholestasis, peliosis hepatis and diffuse hepatitis, with a suggested pathogenic chain from cholestasis and peliosis toward cirrhosis
Animal evidence, but directly on Dianabol itself rather than the class — the structural liver injury that 17α-alkylation produces

Quelle ansehen

8Übersicht1989

Einfach gesagt: In all cases where an effect was achieved, the drug used was methandrostenolone or stanozolol ... The use of AAS as ergogenic drugs must be deprecated because of their marginal effects, the risks of side effects and the unsporting, unethical aspects.

Søe M, Jensen KL, Gluud C · Ugeskrift for laeger (1989)

A review of placebo-controlled studies of anabolic-androgenic steroids on muscle strength, body weight and lean body mass in body-building men
In about half the placebo-controlled studies a significant effect was found — and in every case where an effect was achieved, the drug was methandrostenolone or stanozolol, placing methandrostenolone among the AAS most likely to actually work
Honest counterweight in the same review: the effects were judged marginal and the authors deprecate AAS use given side-effect risk and the unethical/unsporting nature

9Fallstudien=1 · very small study1990

Einfach gesagt: A 30 year old bodybuilder who had been taking anabolic steroids for 18 months presented with bleeding oesophageal varices. Serious liver disease secondary to anabolic steroids including peliosis hepatis, nodular hyperplasia and malignant change is well recognized.

Winwood PJ, Robertson DA, Wright R · Postgraduate medical journal (1990)

Severe-harm counter-evidence in a human: a case report of a 30-year-old bodybuilder on anabolic steroids for 18 months who presented with bleeding oesophageal varices
Frames the worst-case end of AAS hepatotoxicity — serious liver disease including peliosis hepatis, nodular hyperplasia and malignant change, here progressing to portal hypertension and variceal haemorrhage
Documents that the liver injury is not merely reversible enzyme elevation but can produce life-threatening structural and vascular complications in long-term users

Quelle ansehen

In der Forschungsbibliothek ansehen

Methandrostenolone (Dianabol) – Forschung

Überwiegend Mechanismus / Beobachtung

Changes in body composition following therapy of osteoporosis with methandrostenolone.

Effects of methandienone on the performance and body composition of men undergoing athletic training.

Controlled trial of methandienone in treatment of diabetic retinopathy.

[On the use of an anabolic hormone in the acute myocardial infarction. Experimental trial on 486 patients (author's transl)].

"Anabolic" effects of methandienone in men undergoing athletic training.

Serum lipids in power athletes self-administering testosterone and anabolic steroids.

Structural alterations of liver parenchyma induced by anabolic steroids.

[The effect of anabolic androgenic steroids on muscle strength, body weight and lean body mass in body-building men].

Bleeding oesophageal varices associated with anabolic steroid use in an athlete.